Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
InSilico Medicine Cayman TopCo (OTCPK:ISLMF) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
InSilico Medicine Cayman TopCo EBITDA Margin % Related Terms
InSilico Medicine Cayman TopCo EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo EBITDA Margin % Chart
For the Software - Infrastructure subindustry, InSilico Medicine Cayman TopCo's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
InSilico Medicine Cayman TopCo EBITDA Margin % vs Software Industry
For the Software industry and Technology sector, InSilico Medicine Cayman TopCo's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where InSilico Medicine Cayman TopCo's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
InSilico Medicine Cayman TopCo (ISLMF) has a EBITDA Margin % of -1,148.14% as of Dec. 2025. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InSilico Medicine Cayman TopCo and its competitors. According to the industry distribution chart, InSilico Medicine Cayman TopCo ranks #2718 out of 2825 companies in the Software industry, placing it in the top 96.2%.
Is InSilico Medicine Cayman TopCo's EBITDA Margin % too high?
InSilico Medicine Cayman TopCo's current EBITDA Margin % is -1,148.14%. Based on the distribution chart, InSilico Medicine Cayman TopCo ranks #2718 out of 2825 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, InSilico Medicine Cayman TopCo has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does InSilico Medicine Cayman TopCo's EBITDA Margin % compare to ?
According to the Software industry distribution chart, InSilico Medicine Cayman TopCo ranks #2718 out of 2825 companies for EBITDA Margin %. This places InSilico Medicine Cayman TopCo in the lower half of its industry. The industry median EBITDA Margin % is 8.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Software company?
The median EBITDA Margin % among Software companies is 8.21, based on 2,825 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on InSilico Medicine Cayman TopCo and its competitors. For the Software industry, the median EBITDA Margin % is 8.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. InSilico Medicine Cayman TopCo's current EBITDA Margin % is -1,148.14%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InSilico Medicine Cayman TopCo stock overvalued right now?
InSilico Medicine Cayman TopCo (ISLMF) has a current EBITDA Margin % of -1,148.14%. The current EBITDA Margin % is -1,148.14%. InSilico Medicine Cayman TopCo's overall GF Score™ is 13/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For InSilico Medicine Cayman TopCo (ISLMF), the current EBITDA Margin % is -1,148.14% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
InSilico Medicine Cayman TopCo is engaged in applying artificial intelligence (AI) solutions to drug discovery and development by leveraging its proprietary platforms. It has generated multiple clinical-stage or IND-enabling assets using Pharma.AI, an AI-enabled platform that supports drug discovery and development activities. The company operates under a project-based business model, deriving revenue from out-licensing and collaboration arrangements. Geographically, the company generates revenue from multiple countries, with the majority of the revenue coming from United States.
13GF Score
Get the complete analysis for ISLMF
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISLMF has been successfully added to your 
